Intellia Therapeutics Doomed To Fail With CRISPR/Cas9 Treatment For Hepatitis B Virus Seeking Alpha, 08 Oct 2018 Introduction Approximately 257 million people are chronically infected with hepatitis B virus (HBV) globally.